| Followers | 202 |
| Posts | 25627 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Sunday, June 23, 2024 8:31:16 PM
I think that number is over the life of the trials as compassionate use, not in recent times.
As for monies that come in for UK Specials program, my research says that NWBO can’t get that money, but rather it is paid only to a licensed compounding company locally licensed to provide it, not because the company chooses that arrangement but because that is how that program works. Now the company may have worked out that any such funds will pay down previously billed work for validating Flaskworks and expanding Sawston as well as production and that might be substantial amounts as well as potentially paying down local debt for the expansion of Sawston. It is worth asking, but I suspect they can’t really talk too much about it because they are not, as of yet, commercially licensed and likely the MHRA wants absolutely no commercial promotion of this until they are, in fact, licensed. But I doubt there is some immense amount of income they are hiding or misdirecting. That is short talk, but highly unlikely. Shorts love to make such claims, but there is nothing particular about Advent “being private” that would make “hiding income” easier unless you’re literally going to claim FRAUD. And if you’re claiming FRAUD, you’re not really making a long argument but “just curious”… it’s beyond that.
Given LP’s and Les’ backgrounds and positions as well as that this is a public company, while anything is always possible, in my estimation, the notion that this is some giant fraud is ludicrous and fever dream territory. Doubtful Linda Liau would have joined the SAB in that context, and I do not doubt that she likely knows basic details about matters such as that.
I kind of doubt they have had huge income because self-financing is not an easy ask. If it was covered, I believe they would have no problem with demand, but compassionate use has ALWAYS been a problematic category for all of these companies because these treatments are expensive when out of pocket and typically quite out of reach for most patients facing such devastating diseases.
As for monies that come in for UK Specials program, my research says that NWBO can’t get that money, but rather it is paid only to a licensed compounding company locally licensed to provide it, not because the company chooses that arrangement but because that is how that program works. Now the company may have worked out that any such funds will pay down previously billed work for validating Flaskworks and expanding Sawston as well as production and that might be substantial amounts as well as potentially paying down local debt for the expansion of Sawston. It is worth asking, but I suspect they can’t really talk too much about it because they are not, as of yet, commercially licensed and likely the MHRA wants absolutely no commercial promotion of this until they are, in fact, licensed. But I doubt there is some immense amount of income they are hiding or misdirecting. That is short talk, but highly unlikely. Shorts love to make such claims, but there is nothing particular about Advent “being private” that would make “hiding income” easier unless you’re literally going to claim FRAUD. And if you’re claiming FRAUD, you’re not really making a long argument but “just curious”… it’s beyond that.
Given LP’s and Les’ backgrounds and positions as well as that this is a public company, while anything is always possible, in my estimation, the notion that this is some giant fraud is ludicrous and fever dream territory. Doubtful Linda Liau would have joined the SAB in that context, and I do not doubt that she likely knows basic details about matters such as that.
I kind of doubt they have had huge income because self-financing is not an easy ask. If it was covered, I believe they would have no problem with demand, but compassionate use has ALWAYS been a problematic category for all of these companies because these treatments are expensive when out of pocket and typically quite out of reach for most patients facing such devastating diseases.
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
